Omixon is a global molecular diagnostics company, empowering clinical labs with technologies to improve patient outcomes by commercializing disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Join Our Upcoming Webinar – Changes on Allele Frequencies Net Database to Support NGS in Histocompatibility & Immunogenetics
Join us at our Omixon Webinar to discover the changes happening to the allele frequencies database and the impact of NGS on histocompatibility and immunogenetics. The disruptive power of Next Generation Sequencing is reshaping the nature of modern Immunogenetics with the ability to fully characterize the …more
Omixon today announce that their flagship Holotype HLA assay and software solution for HLA typing by Next Generation Sequencing (NGS) has been selected as the HLA typing solution of choice by the Etablissement Français du Sang (the French National Blood …more